Despite advances in the treatment of several tumors, melanoma remains a cancer with a very poor prognosis. Dacarbazine is considered the standard-of-care for metastatic disease and it has been tested in association with both chemotherapeutic and immunologic drugs. Recent efforts have focused on developing novel targeted therapeutic agents, as more information is available regarding molecular biology of this disease. In this review we discuss the systemic therapeutic options for metastatic melanoma and focus on the new targeted drugs.
Bajetta, E., Canova, S., Cortinovis, D. (2007). Metastatic melanoma. CANCER & CHEMOTHERAPY REVIEWS, 2(3), 184-192.
Metastatic melanoma
Cortinovis, D
2007
Abstract
Despite advances in the treatment of several tumors, melanoma remains a cancer with a very poor prognosis. Dacarbazine is considered the standard-of-care for metastatic disease and it has been tested in association with both chemotherapeutic and immunologic drugs. Recent efforts have focused on developing novel targeted therapeutic agents, as more information is available regarding molecular biology of this disease. In this review we discuss the systemic therapeutic options for metastatic melanoma and focus on the new targeted drugs.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
